-
Posted by
Two Blokes Wed at 12:15 PM -
Filed in
Stock
-
1 view
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector\u00ae - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS\u00ae), announced today that Health Canada has granted approval for XIPERE\u00ae (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME).
